Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Hardy

Podiatrist Avon, OH Doctor of Podiatric Medicine

NPI 1023123593 CMS profile 847826

1480 Center Rd, Ste B, Avon, OH 44011

Open in the dashboard

General payments

$2,071,643

391 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Hardy of Avon, OH is reported in the CMS Open Payments database as having received $2,071,643 across 391 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $102,759 37
2024 General $114,593 58
2023 General $393,125 80
2022 General $203,790 62
2021 General $1,072,259 47
2020 General $65,890 36
2019 General $119,227 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Hardy
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Mark Hardy were reported at $102,759. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Mark Hardy Podiatrist median Middle half National median
2019 $119,227 $196 $72–$601 $163
2020 $65,890 $118 $38–$335 $114
2021 $1,072,259 $169 $57–$573 $132
2022 $203,790 $220 $74–$782 $149
2023 $393,125 $208 $71–$635 $160
2024 $114,593 $237 $87–$681 $164
2025 $102,759 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Trilliant Surgical LLC. $1,005,358 20 payments
  2. Stryker Corporation $422,872 264 payments
  3. MedShape, Inc. $388,789 39 payments
  4. Medartis Inc. $204,192 18 payments
  5. Nextremity Solutions Inc. $44,519 6 payments
  6. Zimmer Biomet Holdings, Inc. $3,312 4 payments
  7. Smith+Nephew, Inc. $508 10 payments
  8. Integra LifeSciences Corporation $390 5 payments
  9. Trice Medical, Inc. $295 2 payments
  10. Encore Medical, LP $237 3 payments
  11. Other $1,171 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $1,601,714 27 payments
  2. Consulting Fee $424,316 108 payments
  3. Travel and Lodging $35,434 96 payments
  4. Food and Beverage $9,979 159 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200 1 payment
Products named General payments · program years 2019–2025
  1. Lapidus Correction Jig, Right $361,354 8 payments
  2. APTUS Ortho $155,369 12 payments
  3. VARIAX Trauma & Extremeties $99,508 50 payments
  4. VARIAX Trauma & Extremeties $64,659 20 payments
  5. 7 X 23MM CITRELOCK IMPLANT $52,681 25 payments
  6. ORTHOLOC 2 LAPIFUSE $51,613 43 payments
  7. APTUS Ortho $47,432 5 payments
  8. SALVATION $44,116 13 payments
  9. ANCHORAGE $40,125 12 payments
  10. GRAVITY SYNCHFIX $37,229 15 payments
  11. Other $537,598 354 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

21

Median for Podiatry: 160

Drug cost

$579

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 21 $579

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$8,960

Medicare's payments for the services billed

Medicare patients

44

Average age 71

Services billed

131

19 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 34%
Ischemic heart disease 34%
Chronic kidney disease 34%
Heart failure 27%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

391 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record